KR950700297A - 5-HT3-수용체 길항제로서의 2,6-메타노-2H-퀴놀리진 유도체(2,6-Methano-2H-quinolizin derivative as 5-HT3-receptor antagonist) - Google Patents

5-HT3-수용체 길항제로서의 2,6-메타노-2H-퀴놀리진 유도체(2,6-Methano-2H-quinolizin derivative as 5-HT3-receptor antagonist)

Info

Publication number
KR950700297A
KR950700297A KR1019940702945A KR19940702945A KR950700297A KR 950700297 A KR950700297 A KR 950700297A KR 1019940702945 A KR1019940702945 A KR 1019940702945A KR 19940702945 A KR19940702945 A KR 19940702945A KR 950700297 A KR950700297 A KR 950700297A
Authority
KR
South Korea
Prior art keywords
receptor antagonist
quinolizin
methano
derivative
antagonist
Prior art date
Application number
KR1019940702945A
Other languages
English (en)
Other versions
KR100287933B1 (ko
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of KR950700297A publication Critical patent/KR950700297A/ko
Application granted granted Critical
Publication of KR100287933B1 publication Critical patent/KR100287933B1/ko

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/18—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
KR1019940702945A 1992-02-24 1993-02-03 5-ht3-수용체 길항제로서의 2,6-메타노-2h-퀴놀리진 유도체,이의 제조방법 및 이를 포함하는 약제학적 조성물 KR100287933B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP92400474 1992-02-24
EP92400474.0 1992-02-24
PCT/US1993/000880 WO1993017019A1 (en) 1992-02-24 1993-02-03 2,6-methano-2h-quinolizin derivative as 5-ht3-receptor antagonist

Publications (2)

Publication Number Publication Date
KR950700297A true KR950700297A (ko) 1995-01-16
KR100287933B1 KR100287933B1 (ko) 2001-05-02

Family

ID=8211614

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019940702945A KR100287933B1 (ko) 1992-02-24 1993-02-03 5-ht3-수용체 길항제로서의 2,6-메타노-2h-퀴놀리진 유도체,이의 제조방법 및 이를 포함하는 약제학적 조성물

Country Status (14)

Country Link
EP (1) EP0628043A1 (ko)
JP (1) JPH07504192A (ko)
KR (1) KR100287933B1 (ko)
AU (1) AU675060B2 (ko)
CA (1) CA2130563C (ko)
FI (1) FI105917B (ko)
HU (1) HU216831B (ko)
IL (1) IL104821A (ko)
MX (1) MX9300948A (ko)
NO (1) NO943101D0 (ko)
NZ (1) NZ249346A (ko)
TW (1) TW226374B (ko)
WO (1) WO1993017019A1 (ko)
ZA (1) ZA931146B (ko)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000048597A1 (en) 1999-02-18 2000-08-24 Novartis Ag Systemic use of 5-ht3 receptor antagonists against rheumatic inflammatory processes
US8518962B2 (en) 2005-03-07 2013-08-27 The University Of Chicago Use of opioid antagonists
CA2600350C (en) 2005-03-07 2015-02-10 The University Of Chicago Use of opioid antagonists to attenuate endothelial cell proliferation and migration
US9662325B2 (en) 2005-03-07 2017-05-30 The University Of Chicago Use of opioid antagonists to attenuate endothelial cell proliferation and migration
US8524731B2 (en) 2005-03-07 2013-09-03 The University Of Chicago Use of opioid antagonists to attenuate endothelial cell proliferation and migration

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE129153T1 (de) * 1988-02-23 1995-11-15 Merrell Dow Pharma Verwendung von chinolizin- und chinolizinon- derivaten zur herstellung von arzneimitteln.
EP0517984A1 (en) * 1991-06-11 1992-12-16 Merrell Dow Pharmaceuticals Inc. Derivatives of amide analogs of certain methano bridged quinolizines

Also Published As

Publication number Publication date
IL104821A (en) 1997-01-10
EP0628043A1 (en) 1994-12-14
HUT68249A (en) 1995-06-28
IL104821A0 (en) 1993-06-10
NZ249346A (en) 1995-10-26
FI943872A (fi) 1994-08-23
AU675060B2 (en) 1997-01-23
TW226374B (ko) 1994-07-11
MX9300948A (es) 1993-08-01
KR100287933B1 (ko) 2001-05-02
JPH07504192A (ja) 1995-05-11
HU216831B (hu) 1999-09-28
FI105917B (fi) 2000-10-31
HU9402436D0 (en) 1994-10-28
ZA931146B (en) 1993-09-14
WO1993017019A1 (en) 1993-09-02
CA2130563A1 (en) 1993-09-02
FI943872A0 (fi) 1994-08-23
CA2130563C (en) 1997-11-11
AU3603493A (en) 1993-09-13
NO943101L (no) 1994-08-23
NO943101D0 (no) 1994-08-23

Similar Documents

Publication Publication Date Title
NL300035I1 (nl) Gesubstitueerde thiahzolidinedionderivaten.
DK0680488T3 (da) 2,6-Diaminopurinderivater
FI934610A0 (fi) Ventilsammansaettning foer roerledning, omfattande loestagbart ventilsaete
AT397656B (de) (6,7-substituierte-8-alkoxy-1-cyclopropyl-1,4-
DE69329894D1 (de) Arylamidderivate
FI932516A (fi) Styrkonsol, i synnerhet foer motorfordon
NO932842L (no) 1,4-benzodioksanderivater
FI931747A0 (fi) Reflexkropp, isynnerhet foer vaegmarkeringar
NO920420L (no) 3-quinuklidin-derivater
FI931451A0 (fi) 7-oxo-7h-pyrido(1,2,3-de)(1,4)bensoxazin-6-karboxylsyror och -estrar
DE59308564D1 (de) 2,4-Dialkyl-6-sec-alkylphenole
FI941149A (fi) 2,4-diamino-3-hydroksikarboksyylihapon johdannaisia
KR950700297A (ko) 5-HT3-수용체 길항제로서의 2,6-메타노-2H-퀴놀리진 유도체(2,6-Methano-2H-quinolizin derivative as 5-HT3-receptor antagonist)
FI940607A (fi) Imidatso(5,1-C)(1,4)bentsoksatsin-1-onijohdannaiset 5HT3-antagonisteina
FI950101A (fi) 4-oksa-1-atsabisyklo 3,2,0 -7heptanoni-johdannaiset kasvainten vastaisina aineina
FI923542A (fi) Faestanordning foer klingor, isynnerhet i bestrykningsmaskiner
FI934317A (fi) Farmaceutiska sammansaettningar, vilka innehaoller ej-joniska ytaktiva aemnen
NO922732D0 (no) 3,4-dehydropiperidinderivater
NO932638D0 (no) 21-klor-pregnanderivat
FI935130A0 (fi) Raelsbund vagn med skjuttak, saerskilt foer biltransport
FI266U1 (fi) Kapningsanordning foer aemnesbana, saosom en pappersbana
FI935129A0 (fi) Tvaovaoningsgodsvagn, saerskilt foer biltransport
NO942212D0 (no) 13,14-dihydro-PGF2
DE69219121D1 (de) Karboxamido-(1,2n)-karbocyclo-2-aminotetralinderivate
FI784U1 (fi) Skalkonstruktion, speciellt vaeggkonstruktion, foer byggnad

Legal Events

Date Code Title Description
A201 Request for examination
AMND Amendment
E902 Notification of reason for refusal
AMND Amendment
E601 Decision to refuse application
J201 Request for trial against refusal decision
AMND Amendment
B701 Decision to grant
GRNT Written decision to grant
FPAY Annual fee payment

Payment date: 20130117

Year of fee payment: 13

EXPY Expiration of term